A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
Summary
Third Opinion Trial Synopsis:
This study is testing a new drug called Belantamab mafodotin, which is made of antibodies and drugs that stick to cancer cells. The drug is for people with a type of cancer called multiple myeloma, which can cause kidney problems. The study will test how safe and effective the drug is for people with normal or impaired kidney function. Participants will get the drug through an IV every three weeks and will be monitored for up to 4 years.
This study is testing a new drug called Belantamab mafodotin, which is made of antibodies and drugs that stick to cancer cells. The drug is for people with a type of cancer called multiple myeloma, which can cause kidney problems. The study will test how safe and effective the drug is for people with normal or impaired kidney function. Participants will get the drug through an IV every three weeks and will be monitored for up to 4 years.
*Third Opinion AI Generated Synopsis
Trial Summary
Belantamab mafodotin is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is either at risk or already has renal dysfunction at initial diagnosis. The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in participants with RRMM, who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation ) and have either normal or impaired renal functions. The study will consist of two parts: part 1 will include participants with normal/mildly impaired renal function and severe renal impairment and part 2 will include participants with end-stage renal disease (ESRD), where participants are either not undergoing or require hemodialysis. Participants will be administered belantamab mafodotin at a dose of 2.5 milligram per kilogram (mg/kg) intravenously once in three weeks (Q3W) dosing in Part 1. Based on the Part 1 Safety/Pharmacokinetic (PK) data, Part 2 participants will be administered the dose of either 2.5 mg/kg or 1.9 mg/kg (or other adjusted dose). Participants will be treated with belantamab mafodotin monotherapy until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first. This study will include a screening phase, treatment phase, follow-up phase and a post analysis continued treatment (PACT) phase . The total duration of the study is approximately up to 48 months.
Belantamab mafodotin is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is either at risk or already has renal dysfunction at initial diagnosis. The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in participants with RRMM, who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation ) and have either normal or impaired renal functions. The study will consist of two parts: part 1 will include participants with normal/mildly impaired renal function and severe renal impairment and part 2 will include participants with end-stage renal disease (ESRD), where participants are either not undergoing or require hemodialysis. Participants will be administered belantamab mafodotin at a dose of 2.5 milligram per kilogram (mg/kg) intravenously once in three weeks (Q3W) dosing in Part 1. Based on the Part 1 Safety/Pharmacokinetic (PK) data, Part 2 participants will be administered the dose of either 2.5 mg/kg or 1.9 mg/kg (or other adjusted dose). Participants will be treated with belantamab mafodotin monotherapy until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first. This study will include a screening phase, treatment phase, follow-up phase and a post analysis continued treatment (PACT) phase . The total duration of the study is approximately up to 48 months.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Name: EU GSK Clinical Trials Call Centre
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466
Email: GSKClinicalSupportHD@gsk.com
Phone: +44 (0) 20 8990 4466